Cancer is a large group of diseases that can start in almost any organ or tissue of the body when abnormal cells grow uncontrollably, go beyond their usual boundaries to invade adjoining parts of the body, and/or spread to other organs. The latter process is called metastasizing and is a major cause of death from cancer. A neoplasm and malignant tumor are other common names for cancer. Tumor biomarkers test used in the diagnosis of cancer include, prostate-specific antigen (PSA), circulating tumor cells (CTC), Alfa-fetoprotein test (AFP), CA-19 test for pancreatic cancer, HER-2 test, BRCA test, ALK test for lung cancer, carcinoembryonic test (CEA), EGFR mutation test, and RAS mutation test.
Market Dynamics
The key market players are focusing on the adoption of growth organic strategies such as launching new cancer diagnostics, which is attributed to the growth of the global cancer diagnostics market. For instance, in March 2020, BD (Becton, Dickinson and Company) a medical technology company, and BioMedomics, a privately held, U.S.-based clinical diagnostics company, announced the release of a new point-of-care test that can detect antibodies in blood to confirm current or past exposure to PARP biomarker test in as little as 15 minutes. Furthermore, the development of new technologically advanced products for cancer diagnosis is expected to support market growth. In November 2021, Siemens Healthineers launched Naeotom Alpha, the globe's first photon-counting CT Scannerwith improved resolution as well as a reduction in radiation dose by up to 45% for ultra-high resolution scans. Thus, the segment is expected to show growth in the near future due to the above-mentioned factors.
Furthermore, governments and other healthcare organizations are taking initiatives to provide women between 50 to 75 years access to mammography screening. In June 2020, Fujifilm Medical Systems is Medical equipment manufacturer in the U.S.A. announced a new breast cancer screening awareness campaign focused on early detection of the disease in the United States. The ‘Aspire to Be Fearless’ campaign involves a mobile mammography vehicle traveling throughout the United States to spread Fujifilm’s message. The vehicle includes a waiting room, dressing room, and the latest breast imaging solutions from Fujifilm.
Key features of the study:
- This report provides an in-depth analysis of the global cancer diagnostics market and provides market size (US$ Billion) and compound annual growth rate (CAGR) for the forecast period (2023–2030), considering 2022 as the base year It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
- This study also provides key insights about market drivers, restraints, opportunities, new test launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
- It profiles key players in the global cancer diagnostics market based on the following parameters–Company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include Myriad Genetics, Inc., F. Hoffmann-La Roche AG, Invitae Corporation, NeoGenomics Laboratories, Inc., and BPS Bioscience, Inc. Antibodies Inc., Networks LLC, Beckman Coulter, Inc., Euro Diagnostica AB, F. Hoffmann-La Roche Ltd., Qiagen NV, Siemens Healthcare GmbH, Bio Rad Laboratories Inc., Exagen Inc., Genway Biotech, Inc., Microdrop LLC (imaware), Svar Life Science AB, Abbott Laboratories, Thermo Fisher Scientific Inc., Bio Rad Laboratories Inc., GE Healthcare, Illumina, Inc., Koninklijke Philips N.V., Toshiba Medical Systems Corporation, Agilent Technologies, Inc., Aurora Imaging Technologies, Inc., and Quest Diagnostics.
- Global cancer diagnostics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global cancer diagnostics market.
Detailed Segmentation:
- Global Cancer Diagnostics Market, By Test Type:
- PSA Tests
- CTC Tests
- AFP Tests
- CA-19 Tests
- HER2 Tests
- BRCA Tests
- ALK Tests
- CEA Tests
- EGFR Mutation Tests
- KRAS Mutation Tests
- Others
- Ultrasound
- Mammography
- MRI Scan
- PET Scan
- CT Scan
- Needle Biopsy
- Endoscopic Biopsy
- Bone Marrow Biopsy
- Others
- Tumor Biomarkers Tests
- Imaging
- Biopsy
- Liquid Biopsy
- Immunohistochemistry
- In Situ Hybridization
- Global Cancer Diagnostics Market, By Cancer Type:
- Breast Cancer
- Lung Cancer
- Colorectal Cancer
- Melanoma
- Blood Cancers
- Prostate Cancer
- Ovarian Cancer
- Stomach Cancer
- Liver Cancer
- Others
- Global Cancer Diagnostics Market, By End User:
- Hospital Associated Labs
- Independent Diagnostic Laboratories
- Diagnostic Imaging Centers
- Cancer Research Institutes
- Others
- Global Cancer Diagnostics, By Region:
- North America
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC
- Israel
- Rest of Middle East
- Africa
- South Africa
- Central Africa
- North Africa
- Company Profiles
- Myriad Genetics, Inc
- F. Hoffmann-La Roche AG
- Invitae Corporation
- NeoGenomics Laboratories, Inc.
- BPS Bioscience, Inc.
- Antibodies Inc.
- Networks LLC
- Beckman Coulter, Inc.
- Euro Diagnostica AB
- F. Hoffmann-La Roche Ltd.
- Qiagen NV
- Siemens Healthcare GmbH
- Bio Rad Laboratories Inc.
- Exagen Inc.
- Genway Biotech, Inc.
- Microdrop LLC (imaware)
- Svar Life Science AB
- Thermo Fisher Scientific Inc.
- Bio Rad Laboratories Inc.
- GE Healthcare
- Illumina, Inc.
- Koninklijke Philips N.V.
- Toshiba Medical Systems Corporation
- Agilent Technologies, Inc.
- Aurora Imaging Technologies, Inc.
- Quest Diagnostics.
